Trials / Completed
CompletedNCT05006898
Compound to Control Presbyopia Symptoms
Synergistic Use of Pilocarpine-Brimonidine-Oxymetazoline to Control Presbyopia Symptoms
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Optall Vision · Academic / Other
- Sex
- All
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Low dose compose to control presbyopia symptoms
Detailed description
A los dose compound including pilocarpine, brimonidine and oxymetazoline was use to control presbyopia symptoms compared to pilocarpine and brimonidine in low doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | PBO to control presbyopia symptoms | Low dose PBO to control presbyopia symptoms |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2020-07-01
- Completion
- 2020-07-01
- First posted
- 2021-08-16
- Last updated
- 2021-08-19
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT05006898. Inclusion in this directory is not an endorsement.